EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Biomaterials‐Boosted Immunotherapy for Osteosarcoma

Chao Sun, Shuqiang Li, Jianxun Ding iD

Advanced Healthcare Materials · 2024-09 · 13 (23)

DOI: 10.1002/adhm.202400864 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Healthcare Materials, online erschienen am 05.07.2024. Verfasst von Chao Sun und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, Orthopedic Center, The First Hospital of Jilin University, 1 Xinmin Street, Changchun, 130061, P. R. China. Hauptthemen laut MEDLINE: Osteosarcoma, Immunotherapy, Biocompatible Materials, Bone Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 149 Literaturangaben. Gefördert von: National Key Research and Development Program, National Natural Science Foundation of China, Science and Technology Development Program of Jilin Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteosarcoma (OS) is a primary malignant bone tumor that emanates from mesenchymal cells, commonly found in the epiphyseal end of long bones. The highly recurrent and metastatic nature of OS poses significant challenges to the efficacy of treatment and negatively affects patient prognosis. Currently, available clinical treatment strategies primarily focus on maximizing tumor resection and reducing localized symptoms rather than the complete eradication of malignant tumor cells to achieve ideal outcomes. The biomaterials‐boosted immunotherapy for OS is characterized by high effectiveness and a favorable safety profile. This therapeutic approach manipulates the tumor microenvironments at the cellular and molecular levels to impede tumor progression. This review delves into the mechanisms underlying the treatment of OS, emphasizing biomaterials‐enhanced tumor immunity. Moreover, it summarizes the immune cell phenotype and tumor microenvironment regulation, along with the ability of immune checkpoint blockade to activate the autoimmune system. Gaining a profound comprehension of biomaterials‐boosted OS immunotherapy is imperative to explore more efficacious immunotherapy protocols and treatment options in this setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteosarcomaImmunotherapyBiocompatible MaterialsBone NeoplasmsHumansTumor MicroenvironmentAnimals

Stichwörter der Autor:innen

biomaterialimmune cell phenotype regulationimmune checkpoint blockadeosteosarcoma immunotherapytumor microenvironment modulation

Substanzen

Biocompatible Materials

Autor:innen und Institutionen

  • Department of Orthopedic Surgery, Orthopedic Center, The First Hospital of Jilin University, 1 Xinmin Street, Changchun, 130061, P. R. China.
  • Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun, 130022, P. R. China.

ORCID-Profile: Jianxun Ding

Förderung

  • National Key Research and Development Program
  • National Natural Science Foundation of China
  • Science and Technology Development Program of Jilin Province
  • Provincial Health Specific Project of Jilin Province
  • Specific Project for Health Research Talents of Jilin Province
  • National Key Research and Development Program of China

Zitieren

APA

Sun, C., Li, S., & Ding, J. (2024). Biomaterials‐Boosted Immunotherapy for Osteosarcoma. Advanced Healthcare Materials, 13(23). https://doi.org/10.1002/adhm.202400864

Vancouver

Sun C, Li S, Ding J. Biomaterials‐Boosted Immunotherapy for Osteosarcoma. Advanced Healthcare Materials. 2024;13(23). doi:10.1002/adhm.202400864

BibTeX
@article{Sun2024,
  author = {Sun, Chao and Li, Shuqiang and Ding, Jianxun},
  title = {Biomaterials‐Boosted Immunotherapy for Osteosarcoma},
  journal = {Advanced Healthcare Materials},
  year = {2024},
  volume = {13},
  number = {23},
  doi = {10.1002/adhm.202400864}
}
Kostenlos starten →